Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

US Patent 10766965 · Granted Sep 8, 2020

Estimated economic value: $121,118,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CD38 antibodies for treatment of acute myeloid leukemia2025
Anti-CD38 antibodies for treatment of acute myeloid leukemia2025
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-pos2024
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-pos2024
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-pos2024
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-pos2024
Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-pos2024
Combination therapies with anti-CD38 antibodies2024
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia2023
Methods of treating high risk multiple myeloma2023
Immune modulation and treatment of solid tumors with antibodies that specificall2021
Combination therapies with anti-CD38 antibodies2020